MedTrace Logo

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

NCT02002689 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-05-02

Study results available
· View outcomes & findings →

Summary

The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study

Conditions

  • PTCH1 or SMO Activated Solid and Hematologic Tumors

Interventions

DRUG

LDE225

LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02002689 on ClinicalTrials.gov